Senti Biosciences Inc (SNTI) - Total Liabilities
Based on the latest financial reports, Senti Biosciences Inc (SNTI) has total liabilities worth $44.56 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Senti Biosciences Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Senti Biosciences Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Senti Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Senti Biosciences Inc.
Senti Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Senti Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thriven Global Bhd
KLSE:7889
|
Malaysia | RM93.20 Million |
|
FELIX Group Holdings Ltd
AU:FLX
|
Australia | AU$15.19 Million |
|
Wahana Inti MakmurTbk PT
JK:NASI
|
Indonesia | Rp11.68 Billion |
|
Traws Pharma Inc
NASDAQ:TRAW
|
USA | $9.78 Million |
|
Jcurve Solutions Ltd
AU:JCS
|
Australia | AU$7.10 Million |
|
Fiberweb (India) Limited
NSE:FIBERWEB
|
India | Rs166.67 Million |
|
Praxis Home Retail Limited
NSE:PRAXIS
|
India | Rs2.60 Billion |
|
Turnstone Biologics Corp. Common Stock
NASDAQ:TSBX
|
USA | $6.34 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Senti Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Senti Biosciences Inc net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.51 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Senti Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Senti Biosciences Inc (2019–2024)
The table below shows the annual total liabilities of Senti Biosciences Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $72.19 Million | +37.32% |
| 2023-12-31 | $52.57 Million | -1.79% |
| 2022-12-31 | $53.53 Million | +47.36% |
| 2021-12-31 | $36.33 Million | -66.07% |
| 2020-12-31 | $107.06 Million | +498.86% |
| 2019-12-31 | $17.88 Million | -- |
About Senti Biosciences Inc
Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications w… Read more